Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LONP1 | P36776 | 12/20 | 0.71 |
| ▸ | PSMB5 | P28074 | 11/20 | 0.71 |
| ▸ | PSMB8 | P28062 | 10/20 | 0.71 |
| ▸ | PSMB9 | P28065 | 10/20 | 0.71 |
| ▸ | PSMB6 | P28072 | 10/20 | 0.71 |
| ▸ | PSMB10 | P40306 | 10/20 | 0.71 |
| ▸ | PSMB11 | A5LHX3 | 9/20 | 0.71 |
| ▸ | PSMA7 | O14818 | 9/20 | 0.71 |
| ▸ | PSMB1 | P20618 | 9/20 | 0.71 |
| ▸ | PSMA1 | P25786 | 9/20 | 0.71 |
| ▸ | PSMA2 | P25787 | 9/20 | 0.71 |
| ▸ | PSMA3 | P25788 | 9/20 | 0.71 |
| ▸ | PSMA4 | P25789 | 9/20 | 0.71 |
| ▸ | PSMA5 | P28066 | 9/20 | 0.71 |
| ▸ | PSMB4 | P28070 | 9/20 | 0.71 |
| ▸ | PSMB3 | P49720 | 9/20 | 0.71 |
| ▸ | PSMB2 | P49721 | 9/20 | 0.71 |
| ▸ | PSMA6 | P60900 | 9/20 | 0.71 |
| ▸ | PSMA8 | Q8TAA3 | 9/20 | 0.71 |
| ▸ | PSMB7 | Q99436 | 9/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL535688 | 1.00 | LONP1 (0.71) | LONP1PSMB5PSMB8PSMB9PSMB6 | |
| SCHEMBL3926604 | 0.99 | LONP1 (0.69) | LONP1PSMB5PSMB8PSMB9PSMB6 | |
| SCHEMBL2127363 | 0.95 | LONP1 (0.76) | LONP1PSMB5PSMB8PSMB9PSMB6 | |
| SCHEMBL2127299 | 0.90 | PSMB5 (0.69) | LONP1PSMB5PSMB8PSMB9PSMB6 | |
| SCHEMBL2127921 | 0.90 | PSMB5 (0.69) | LONP1PSMB5PSMB8PSMB9PSMB6 | |
| SCHEMBL680573 | 0.90 | LONP1 (0.68) | LONP1PSMB5PSMB8PSMB9PSMB6 | |
| SCHEMBL8513905 | 0.90 | PSMB5 (0.58) | LONP1PSMB5PSMB8PSMB9PSMB6 | |
| SCHEMBL1688075 | 0.90 | LONP1 (0.68) | LONP1PSMB5PSMB8PSMB9PSMB6 | |
| SCHEMBL13078869 | 0.90 | CTSL (0.71) | LONP1PSMB5PSMB8PSMB9PSMB6 | |
| SCHEMBL2127762 | 0.89 | PSMB5 (0.73) | LONP1PSMB5PSMB8PSMB9PSMB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4008721-B1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | MILLENNIUM PHARM INC (US) | 2024-01-03 | — | — | EP | claimed |
| CN-114644682-A | Preparation method of bortezomib | 海南双成药业股份有限公司 | 2022-06-21 | — | — | CN | claimed |
| EP-4008721-A1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | Millennium Pharmaceuticals, Inc. (US) | 2022-06-08 | — | — | EP | claimed |
| EP-3385267-B1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | MILLENNIUM PHARM INC (US) | 2021-09-29 | — | — | EP | claimed |
| EP-3385267-A1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | Millennium Pharmaceuticals, Inc. (US) | 2018-10-10 | — | — | EP | claimed |
| US-10000529-B2 | Synthesis of boronic ester and acid compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | claimed |
| US-20180044377-A1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. | 2018-02-15 | — | — | US | claimed |
| CN-107474062-A | The synthesis of the ester and acid compound of boron | 千禧药品公司 | 2017-12-15 | — | — | CN | claimed |
| CN-106279355-A | The preparation technology of bortezomib | 北京博时安泰科技发展有限公司 | 2017-01-04 | — | — | CN | claimed |
| CN-102659919-B | A kind of synthetic method of Velcade | HEFEI UNIVERSITY OF TECHNOLOGY (CN) | 2016-03-30 | — | — | CN | claimed |
| CN-103059054-A | Synthetic method of bortezomib | HANGZHOU PING HE AN KANG PHARMACEUTICAL CO LTD | 2013-04-24 | — | — | CN | claimed |
| CN-102659919-A | Synthetic method of bortezomib | UNIV HEFEI TECHNOLOGY | 2012-09-12 | — | — | CN | claimed |
| JP-2011529904-A | — | — | 2011-12-15 | — | — | JP | claimed |
| EP-2377868-A1 | Synthesis of Bortezomib | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-10-19 | — | — | EP | claimed |
| EP-2309854-A1 | ACCELERATED THERAPY | Gloucester Pharmaceuticals, Inc. (US) | 2011-04-20 | — | — | EP | claimed |
| WO-2010014819-A1 | ACCELERATED THERAPY | GLOUCESTER PHARMACEUTICALS, INC. (US) | 2010-02-04 | — | — | WO | claimed |
| EP-1326632-A2 | AGENTS FOR THE TREATMENT OF VIRAL INFECTIONS | VIROMICS GMBH (DE) | 2003-07-16 | — | — | EP | claimed |
| WO-2002030455-A2 | AGENTS FOR THE TREATMENT OF VIRAL INFECTIONS | VIROMICS GMBH (DE) | 2002-04-18 | — | — | WO | claimed |
| EP-2318419-B2 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-10-30 | — | — | EP | disclosed |
| EP-0229667-A2 | Peptidylaminodiols | ABBOTT LABORATORIES (US) | 1987-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000529-B2 | Synthesis of boronic ester and acid compounds | BTD, BCL6, BRAP | LONP1 2151/4885PSMB5 17/4885PSMB8 43/4885 |
| US-20180044377-A1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | BTD, BCL6, BRAP | LONP1 2151/4885PSMB5 17/4885PSMB8 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.